The Middle East syphilis testing market size was estimated at USD 21.25 million in 2024 and is projected to reach USD 55.01 million by 2033, growing at a CAGR of 11.47% from 2025 to 2033. Growing public health awareness and government-led initiatives are driving demand for syphilis diagnostics across the Middle East. The region has placed infectious disease control at the center of its healthcare priorities, with syphilis screening integrated into antenatal care, premarital testing, and expatriate health checks in many Gulf countries.
Rising mobility of populations, large expatriate communities, and cross-border labor flows have made early detection and prevention programs essential. Concurrently, healthcare providers in the region are rapidly adopting advanced diagnostic technologies, including point-of-care rapid tests and laboratory-based immunoassays, to strengthen surveillance and ensure timely treatment.
Saudi Arabia’s health system emphasizes centralized lab capacity and antenatal screening within public hospitals; demand for high-quality immunoassays and molecular confirmatory testing remains strong. Simultaneously, Gulf Cooperation Council (GCC) initiatives and private hospitals are open to rapid POC solutions for screening travelers, migrant worker clinics, and perinatal care. Market entry requires regulatory clearance, adherence to national procurement, and partnerships with major hospital groups. Opportunities exist for accredited dual HIV/syphilis rapid tests that meet Saudi regulatory standards and can be deployed in maternal health and occupational-health screening programs.
The prevalence of syphilis in the Middle East and North Africa (MENA) is higher than anticipated given regional norms, but it is comparable to global levels. According to a 2024 study, the prevalence was 0.48% in the general population overall, but significantly higher rates were found in high-risk groups such as female sex workers (FSW) and men who have sex with men (MSM). Although prevalence is decreasing, it is not doing so quickly enough to reach international goals. Testing includes techniques like rapid plasma reagin (RPR) and Treponema pallidum-specific tests to identify current and previous infections.
Syphilis testing in the UAE utilizes Rapid Plasma Reagin (RPR) and Treponema pallidum Hemagglutination (TPHA) tests, and a recent study in 2016 showed a 0.51% prevalence among expatriate workers undergoing health checks. Another study in 2021 found a 0.45% syphilis seropositivity rate among individuals screened in a tertiary hospital, with higher rates among non-Saudi expatriates compared to Saudis.
This product will be delivered within 2 business days.
Rising mobility of populations, large expatriate communities, and cross-border labor flows have made early detection and prevention programs essential. Concurrently, healthcare providers in the region are rapidly adopting advanced diagnostic technologies, including point-of-care rapid tests and laboratory-based immunoassays, to strengthen surveillance and ensure timely treatment.
Saudi Arabia’s health system emphasizes centralized lab capacity and antenatal screening within public hospitals; demand for high-quality immunoassays and molecular confirmatory testing remains strong. Simultaneously, Gulf Cooperation Council (GCC) initiatives and private hospitals are open to rapid POC solutions for screening travelers, migrant worker clinics, and perinatal care. Market entry requires regulatory clearance, adherence to national procurement, and partnerships with major hospital groups. Opportunities exist for accredited dual HIV/syphilis rapid tests that meet Saudi regulatory standards and can be deployed in maternal health and occupational-health screening programs.
The prevalence of syphilis in the Middle East and North Africa (MENA) is higher than anticipated given regional norms, but it is comparable to global levels. According to a 2024 study, the prevalence was 0.48% in the general population overall, but significantly higher rates were found in high-risk groups such as female sex workers (FSW) and men who have sex with men (MSM). Although prevalence is decreasing, it is not doing so quickly enough to reach international goals. Testing includes techniques like rapid plasma reagin (RPR) and Treponema pallidum-specific tests to identify current and previous infections.
Syphilis testing in the UAE utilizes Rapid Plasma Reagin (RPR) and Treponema pallidum Hemagglutination (TPHA) tests, and a recent study in 2016 showed a 0.51% prevalence among expatriate workers undergoing health checks. Another study in 2021 found a 0.45% syphilis seropositivity rate among individuals screened in a tertiary hospital, with higher rates among non-Saudi expatriates compared to Saudis.
Middle East Syphilis Testing Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the Middle East syphilis testing market based on technology, location of testing, and region:- Technology Outlook (USD Million, 2021-2033)
- Molecular Diagnostics
- Immunoassay
- Others
- Location of Testing Outlook (USD Million, 2021-2033)
- Laboratory Testing
- Point of Care Testing
- Regional Outlook (USD Million, 2021-2033)
- Middle East
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Middle East Syphilis Testing Market: Methodology and Scope
Chapter 2. Middle East Syphilis Testing Market: Executive Summary
Chapter 3. Middle East Syphilis Testing Market Variables, Trends, & Scope
Chapter 4. Middle East Syphilis Testing Market: Technology Estimates & Trend Analysis
Chapter 5. Middle East Syphilis Testing Market: Location of Testing Estimates & Trend Analysis
Chapter 6. Middle East Syphilis Testing Market: Regional Business Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Middle East Syphilis Testing market report include:- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Bio-Rad Laboratories, Inc.
- Siemens Healthineers AG
- Danaher Corporation (Beckman Coulter)
- Thermo Fisher Scientific Inc.
- bioMérieux SA
- OraSure Technologies, Inc.
- Chembio Diagnostics, Inc.
- SD Biosensor, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 236 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 21.25 Million |
| Forecasted Market Value ( USD | $ 55.01 Million |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Middle East |
| No. of Companies Mentioned | 11 |
